Literature DB >> 32737522

Monitoring of high-flow nasal cannula for SARS-CoV-2 severe pneumonia: less is more, better look at respiratory rate.

Damien Blez1, Anne Soulier1, Francis Bonnet1, Etienne Gayat2, Marc Garnier3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32737522      PMCID: PMC7393342          DOI: 10.1007/s00134-020-06199-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, The main clinical features of severe Corona Virus Disease 2019 (COVID-19) are hypoxaemia and respiratory failure [1]. Some COVID-19 patients may benefit from high-flow oxygen through nasal cannula (HFNC) [2]. However, it is critical not to delay intubation when it becomes necessary, otherwise increased mortality may be observed [3]. The “ROX index”, dividing the oxygen saturation by the inspired oxygen fraction and the respiratory rate (SpO2/FiO2/RR), has been proposed to monitor patients treated with HFNC [4, 5]. We conducted a monocentric prospective observational study to assess the accuracy of several parameters, including the ROX, to detect HFNC failure in the specific setting of SARS-CoV-2-related severe pneumonia. All the patients admitted in our intensive care unit with proven COVID-19 requiring HFNC during March and April 2020 were included. Clinical parameters were collected within the 4 h before, and 30 min, 2 and 6 h after HFNC initiation. HFNC was systematically initiated at 60 L min−1/FiO2 1. Then, FiO2 was decreased hourly, maintaining 92% ≤ SpO2 ≤ 98%, down to 0.4, at which point flow was progressively reduced until weaning. “HFNC failure” was defined as the need for invasive mechanical ventilation within 7 days of HFNC onset. Thirty patients were included (Table S1 in the eSupplement). Prior to HFNC, the median [IQR] RR was 30 [26-36]/min and O2 flow was 10 [8-15] L/min. Sixteen patients met the outcome “HFNC failure” after 1 [0.9–2.5] day. The remaining 14 patients were weaned after 5 [4-7] days. Although not different before HFNC onset, RR was significantly lower at H0.5 in the “weaned” compared to the “failure” group (24 [20-24] vs. 31 [27-34]/min, p = 0.004). The area under the receiver operating characteristic curve (AUROC) of RR at H0.5 was 0.81 95% CI [0.61–0.96] (Fig. 1), with a best cut-off value at 26/min (sensitivity 75%, specificity 85%, positive likelihood ratio 4.9). RR at H2 and H6 was less informative (Table S2). ROX H0.5 had an AUROC of 0.78 [0.58–0.95]. Performance characteristics of ROX H0.5 using the previous published cut-off value of 4.88 [4, 5] were 81% sensitivity, 38% specificity and a positive likelihood ratio of 1.3. Neither the ROX at H2 and H6, nor its changes between H0 and H0.5, H0.5–H2, and H2–H6, had better diagnostic performance than RR at H0.5 (Tables S1 and S2). Results for the other parameters are reported in Fig. 1 and in the eSupplement.
Fig. 1

Receiver Operating Characteristic (ROC) curves for the principal clinical parameters for the diagnosis of high-flow nasal cannula failure. SpO oxygen saturation, HR heart rate, FiO inspired oxygen fraction, ROX “Respiratory rate-Oxygenation” index

Receiver Operating Characteristic (ROC) curves for the principal clinical parameters for the diagnosis of high-flow nasal cannula failure. SpO oxygen saturation, HR heart rate, FiO inspired oxygen fraction, ROX “Respiratory rate-Oxygenation” index The main limitations of this derivation cohort are its monocentric design and the small number of patients included. These results should be confirmed in future validation cohorts before proposing to intubate patients who are still very tachypneic as early as 30 min after HFNC onset. However, our results suggest that monitoring COVID-19 patients requiring HFNC with the ROX index did not add value to RR alone. This is in agreement with a possible lower diagnostic value of the ROX in viral pneumonia [4]. This may be because the ROX was mostly dependent on RR, as FiO2 was persistently high during the first hours of HFNC [6] and as COVID-19 patients may present higher dead space due to diffuse pulmonary thrombi [7]. In addition, one-third of the patients had 100% SpO2 despite the 92% ≤ SpO2 ≤ 98% target, which may have decreased the contribution of the SpO2/FiO2 in the diagnostic accuracy of the ROX. Our results highlight the need for continuous monitoring of COVID-19 patients requiring HFNC, and suggested reinforcing the surveillance of patients with a RR ≥ 26/min half an hour after HFNC onset, as it may be associated with a high risk of intubation. In conclusion, among the respiratory parameters available for monitoring COVID-19 patients treated with HFNC, using the RR is accurate and simple, thus “being most likely the right solution” according to Occam’s razor. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 18 kb) Supplementary file2 (DOCX 12 kb) Supplementary file3 (DOCX 14 kb)
  7 in total

1.  An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy.

Authors:  Oriol Roca; Berta Caralt; Jonathan Messika; Manuel Samper; Benjamin Sztrymf; Gonzalo Hernández; Marina García-de-Acilu; Jean-Pierre Frat; Joan R Masclans; Jean-Damien Ricard
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

2.  Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.

Authors:  Byung Ju Kang; Younsuck Koh; Chae-Man Lim; Jin Won Huh; Seunghee Baek; Myongja Han; Hyun-Suk Seo; Hee Jung Suh; Ga Jin Seo; Eun Young Kim; Sang-Bum Hong
Journal:  Intensive Care Med       Date:  2015-02-18       Impact factor: 17.440

3.  Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index.

Authors:  Oriol Roca; Jonathan Messika; Berta Caralt; Marina García-de-Acilu; Benjamin Sztrymf; Jean-Damien Ricard; Joan R Masclans
Journal:  J Crit Care       Date:  2016-05-31       Impact factor: 3.425

4.  Nasal High-Flow Therapy: Role of FiO2 in the ROX Index.

Authors:  Stanislav Tatkov
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

5.  COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.

Authors:  Hooman D Poor; Corey E Ventetuolo; Thomas Tolbert; Glen Chun; Gregory Serrao; Amanda Zeidman; Neha S Dangayach; Jeffrey Olin; Roopa Kohli-Seth; Charles A Powell
Journal:  Clin Transl Med       Date:  2020-06-05

6.  The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China.

Authors:  Ke Wang; Wei Zhao; Ji Li; Weiwei Shu; Jun Duan
Journal:  Ann Intensive Care       Date:  2020-03-30       Impact factor: 6.925

7.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

  7 in total
  8 in total

1.  Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.

Authors:  João João Mendes; José Artur Paiva; Filipe Gonzalez; Paulo Mergulhão; Filipe Froes; Roberto Roncon; João Gouveia
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24

2.  Effectiveness of the use of a high-flow nasal cannula to treat COVID-19 patients and risk factors for failure: a meta-analysis.

Authors:  Dong-Yang Xu; Bing Dai; Wei Tan; Hong-Wen Zhao; Wei Wang; Jian Kang
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 5.158

3.  Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm.

Authors:  J C Winck; R Scala
Journal:  Pulmonology       Date:  2021-01-20

4.  Factors associated with mechanical ventilation in SARS-CoV-2 patients treated with high-flow nasal cannula oxygen and outcomes.

Authors:  Xavier Leroux; Maud Schock; Olivier Augereau; Henry Lessire; Charles Bouterra; Lounis Belilita; Pierre Rerat; Antonio Alvarez; Martin Martinot; Victor Gerber
Journal:  J Med Virol       Date:  2021-11-17       Impact factor: 20.693

5.  High-Flow Nasal Cannula Treatment in Patients with COVID-19 Acute Hypoxemic Respiratory Failure: A Prospective Cohort Study.

Authors:  Mohammed S Alshahrani; Hassan M Alshaqaq; Jehan Alhumaid; Ammar A Binammar; Khalid H AlSalem; Abdulazez Alghamdi; Ahmed Abdulhady; Moamen Yehia; Amal AlSulaibikh; Mohammed Al Jumaan; Waleed H Albuli; Talal Ibrahim; Abdullah A Yousef; Yousef Almubarak; Waleed Alhazzani
Journal:  Saudi J Med Med Sci       Date:  2021-08-31

6.  The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis.

Authors:  Xiaoyang Zhou; Jiequan Liu; Jianneng Pan; Zhaojun Xu; Jianfei Xu
Journal:  BMC Pulm Med       Date:  2022-04-01       Impact factor: 3.317

7.  COVID-19 pneumonia and ROX index: Time to set a new threshold for patients admitted outside the ICU. Authors' reply.

Authors:  M L Vega; R Dongilli; G Olaizola; N Colaianni; M C Sayat; L Pisani; M Romagnoli; G Spoladore; I Prediletto; G Montiel; S Nava
Journal:  Pulmonology       Date:  2021-07-29

Review 8.  Non-invasive Respiratory Support in COVID-19: A Narrative Review.

Authors:  Manel Luján; Javier Sayas; Olga Mediano; Carlos Egea
Journal:  Front Med (Lausanne)       Date:  2022-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.